CHO vs HEK293
HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency. HEK293 cells are amenable to a variety of transfection methods. In terms of growth and protein production efficiency, HEK293 cells are quite poor. Not convinced? Search FDA website for the number of human proteins or antibodies manufactured using HEK293 cells. You won't find many.
CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record. The biggest drawback of CHO is that the cells are hard to transfect. As such, CHO cells have been primarily used for CHO stable production, not transient.
TunaCHO™ technology platform solves the technical problem of low transient transfection efficiency. We are able to achieve production yield greater than 2 gram per liter in shake flasks. We further have shown consistent PTM profiles between TunaCHO™ and CHO-GSN™. Needless to say, LakePharma favors CHO over HEK293 as a transient protein production platform.
Recombinant antibody expression with TunaCHO™ process is significantly higher than HEK293 cells.
Click here to learn more about our proprietary TunaCHO™ platform and detailed services.
To download our TunaCHO™ presentation click here.